Need professional-grade analysis? Visit stockanalysis.com
$2.82B
N/A
354
N/A
Arcutis Biotherapeutics Inc (ARQT) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $23.40, down 4.61% from the previous close.
Over the past year, ARQT has traded between a low of $13.04 and a high of $31.20. The stock has gained 61.9% over this period. It is currently 25.0% below its 52-week high.
Arcutis Biotherapeutics Inc has a market capitalization of $2.82B.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Side-by-side comparison against top Healthcare peers.